Literature DB >> 7562475

In vitro formation, disposition and toxicity of N-acetoxy-sulfamethoxazole, a potential mediator of sulfamethoxazole toxicity.

H Nakamura1, J Uetrecht, A E Cribb, M A Miller, N Zahid, J Hill, P D Josephy, D M Grant, S P Spielberg.   

Abstract

Variation in the formation and disposition of the hydroxylamine of (SMX-HA) is thought to play an important role in the pathogenesis of sulfamethoxazole (SMX)-induced idiosyncratic adverse drug reactions. We hypothesized that, in analogy to carcinogenic arylamines, SMX-HA might be further converted to an electrophilic N-acetoxy metabolite which could play a role in mediating SMX toxicity. Accordingly, we chemically synthesized N-acetoxy-SMX, and examined the characteristics of its formation, metabolism, cytotoxicity and mutagenicity in human and bacterial test systems. The human arylamine N-acetyl-transferases, (NAT)1 and NAT2, were capable of converting SMX-HA to N-acetoxy-SMX. NAT1 and NAT2 possessed similar affinities for SMX-HA (apparent Km values of 650 and 520 microM, respectively), but the apparent maximal velocity of the NAT1-mediated acetylation was higher than that of NAT2. (1332 vs. 37 nmol/min/U of immunoreactive NAT protein). Human peripheral blood mononuclear cells 12,000 x g supernatant fractions converted N-acetoxy-SMX mainly back to SMX-HA, and also to a lesser extent to SMX, at clinically relevant concentrations. Similar pathways were observed in human hepatic cytosolic fractions. In a cytotoxicity assay, N-acetoxy-SMX was significantly more toxic to human peripheral blood mononuclear cells than SMX-HA (16.6 vs. 11.5% dead cells at a concentration of 300 microM). N-acetoxy-SMX was weakly mutagenic to the Salmonella typhimurium TA100 strain in the Ames test. These data suggest that the N-acetoxy metabolites of sulfonamides could potentially play a role in mediating sulfonamide idiosyncratic adverse drug reactions.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7562475

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  14 in total

1.  N-acetyltransferases: pharmacogenetics and clinical consequences of polymorphic drug metabolism.

Authors:  S P Spielberg
Journal:  J Pharmacokinet Biopharm       Date:  1996-10

2.  Suboptimal cotrimoxazole prophylactic concentrations in HIV-infected children according to the WHO guidelines.

Authors:  Claire Pressiat; Veronique Mea-Assande; Caroline Yonaba; Jean-Marc Treluyer; Désiré-Lucien Dahourou; Madeleine Amorissani-Folquet; Stéphane Blanche; François Eboua; Diarra Ye; Gabrielle Lui; Karen Malateste; Yi Zheng; Valeriane Leroy; Déborah Hirt
Journal:  Br J Clin Pharmacol       Date:  2017-09-20       Impact factor: 4.335

3.  Influence of NAT2 polymorphisms on sulfamethoxazole pharmacokinetics in renal transplant recipients.

Authors:  Hideaki Kagaya; Masatomo Miura; Takenori Niioka; Mitsuru Saito; Kazuyuki Numakura; Tomonori Habuchi; Shigeru Satoh
Journal:  Antimicrob Agents Chemother       Date:  2011-11-21       Impact factor: 5.191

4.  Human N-acetyltransferase 1 *10 and *11 alleles increase protein expression through distinct mechanisms and associate with sulfamethoxazole-induced hypersensitivity.

Authors:  Danxin Wang; Michael F Para; Susan L Koletar; Wolfgang Sadee
Journal:  Pharmacogenet Genomics       Date:  2011-10       Impact factor: 2.089

5.  Slow acetylator phenotype and genotype in HIV-positive patients with sulphamethoxazole hypersensitivity.

Authors:  Ana Alfirevic; Anne C Stalford; F Javier Vilar; Ed G L Wilkins; B Kevin Park; Munir Pirmohamed
Journal:  Br J Clin Pharmacol       Date:  2003-02       Impact factor: 4.335

6.  Polymorphism of N-acetyltransferase 1 and correlation between genotype and phenotype in a Thai population.

Authors:  Veerapol Kukongviriyapan; Auemduan Prawan; Benjamart Warasiha; Wichittra Tassaneyakul; Jareerat Aiemsa-ard
Journal:  Eur J Clin Pharmacol       Date:  2003-07-19       Impact factor: 2.953

Review 7.  Pharmacogenomics: marshalling the human genome to individualise drug therapy.

Authors:  W E Evans
Journal:  Gut       Date:  2003-05       Impact factor: 23.059

8.  Polymorphism in glutamate cysteine ligase catalytic subunit (GCLC) is associated with sulfamethoxazole-induced hypersensitivity in HIV/AIDS patients.

Authors:  Danxin Wang; Amanda Curtis; Audrey C Papp; Susan L Koletar; Michael F Para
Journal:  BMC Med Genomics       Date:  2012-07-23       Impact factor: 3.063

Review 9.  Pharmacogenetics: the therapeutic drug monitoring of the future?

Authors:  M H Ensom; T K Chang; P Patel
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 5.577

Review 10.  Hepatic safety of antibiotics used in primary care.

Authors:  Raúl J Andrade; Paul M Tulkens
Journal:  J Antimicrob Chemother       Date:  2011-05-17       Impact factor: 5.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.